Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's denosumab shows bone benefit in men

This article was originally published in Scrip

Executive Summary

Amgen's denosumab increases bone mineral density and reduces fracture incidence in men undergoing androgen-deprivation therapy (ADT) for prostate cancer, top-line results from a pivotal Phase III study suggest.

You may also be interested in...



Amgen reveals more details of denosumab's fracture benefit

Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.

Targacept/AstraZeneca Alzheimer's hope fails in Phase II

Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.

Gilead must conduct another study of cystic fibrosis drug, FDA says

Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.

Topics

Related Companies

UsernamePublicRestriction

Register

SC030971

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel